+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Radiopharmaceuticals Market Report and Forecast 2023-2031

  • PDF Icon

    Report

  • 147 Pages
  • May 2023
  • Region: Global
  • Expert Market Research
  • ID: 5798011
The global radiopharmaceuticals market value was USD 5 billion in 2022, driven by the increasing prevalence of chronic diseases across the globe. The market value is anticipated to grow at a CAGR of 7.50% during the forecast period of 2023-2031 to achieve a value of USD 9.53 billion by 2031.

Radiopharmaceuticals: Introduction

Radiopharmaceuticals, also known as radioactive drugs or radiotracers, are a group of pharmaceutical agents containing radioactive isotopes that are used in nuclear medicine for the diagnosis and treatment of various diseases, such as cancer, cardiovascular disorders, and neurological conditions. Radiopharmaceuticals emit radiation that can be detected by imaging devices, such as positron emission tomography (PET) and single-photon emission computed tomography (SPECT) scanners, enabling physicians to visualize the functioning of organs and tissues, and identify abnormalities at an early stage.

Radiopharmaceuticals Market Scenario

The global radiopharmaceuticals market has experienced significant growth in recent years, driven by factors such as the increasing prevalence of chronic diseases, rising awareness about the benefits of early diagnosis, and advancements in nuclear medicine. Furthermore, the development of novel radiopharmaceuticals, expansion of therapeutic applications, and growing investments in research and development have contributed to the market's expansion.

North America: The largest market for radiopharmaceuticals, driven by factors such as the advanced healthcare infrastructure, a strong focus on research and development, and the presence of major radiopharmaceutical manufacturers.

Europe: The second-largest market, with increasing demand for radiopharmaceuticals due to growing awareness about the benefits of early diagnosis and a supportive regulatory framework.

Asia-Pacific: Expected to witness the highest growth rate due to factors such as a rapidly aging population, increasing prevalence of chronic diseases, and growing investments in healthcare infrastructure.

Radiopharmaceuticals Market Segmentations

Market Breakup by Product Type

Diagnostic Nuclear Medicine

  • SPECT Radiopharmaceuticals
  • Technetium-99m
  • Thallium-201
  • Gallium-67
  • Iodine-123
  • Other

PET Radiopharmaceuticals

  • F-18
  • RU-82
  • Others

Therapeutic Nuclear Medicine

  • Alpha Emitters
  • Ra-223

Brachytherapy Isotopes

  • Intoiodine-125
  • Palladium-103
  • Cesium-131
  • Iridium-192
  • Other brachytherapy isotopes

Beta Emitters

  • Intoiodine-131
  • Yttrium-90
  • Samarium-153
  • Lutetium-177
  • Rhenium-186
  • Other beta emitters

Market Breakup by Applications

  • Diagnostic Applications

SPECT Applications

  • Cardiology
  • Bone Scans
  • Thyroid Applications
  • Pulmonary Scans
  • Other SPECT Applications

PET applications

  • Oncology
  • Cardiology
  • Neurology
  • Other PET applications

Therapeutic Applications

  • Thyroid Indications
  • Bone Metastasis
  • Lymphoma
  • Endocrine Tumors
  • Other Indications

Market Breakup by Volume Assessment

  • Diagnostic Procedures
  • Therapeutic Procedures

Market Breakup by Source

  • Nuclear Rectors
  • Cyclotrons

Market Breakup by End User

  • Hospitals
  • Ambulatory Surgical Centres
  • Diagnostic Centres
  • Cancer Research Institutes
  • Others

Market Breakup by Region

North America

  • United States of America
  • Canada

Europe

  • United Kingdom
  • Germany
  • France
  • Italy
  • Others

Asia Pacific

  • China
  • Japan
  • India
  • ASEAN
  • Australia
  • Others

Latin America

  • Brazil
  • Argentina
  • Mexico
  • Others

Middle East and Africa

  • Saudi Arabia
  • United Arab Emirates
  • Nigeria
  • South Africa
  • Others

Key Trends in the Radiopharmaceuticals Market

Some key trends of the market are as follows:
  • Development of novel radiopharmaceuticals: The introduction of new radiopharmaceuticals with improved diagnostic and therapeutic properties has expanded the range of clinical applications and driven market growth
  • Expansion of therapeutic applications: The increasing use of radiopharmaceuticals for targeted cancer therapy, such as peptide receptor radionuclide therapy (PRRT) and radioimmunotherapy, has contributed to market expansion
  • Advancements in nuclear medicine: Technological advancements in imaging devices and the growing adoption of hybrid imaging techniques, such as PET/CT and SPECT/CT, have improved the accuracy and reliability of radiopharmaceutical-based diagnostics

Radiopharmaceuticals Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
  • Cardinal Health
  • GE Healthcare
  • Lantheus Medical Imaging
  • Bayer AG
  • Bracco Imaging
  • Nordion
  • NTP Radioisotopes
  • NorthStar Medical Radioisotopes
  • Eckert & Ziegler
  • Braun Melsungen AG
  • Smith Nephew
  • Zimmer Biomet
  • Otto Bock Healthcare

Table of Contents

1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Radiopharmaceuticals Market Overview
3.1 Global Radiopharmaceuticals Market Historical Value (2016-2022)
3.2 Global Radiopharmaceuticals Market Forecast Value (2023-2031)
4 Global Radiopharmaceuticals Market Landscape
4.1 Global Radiopharmaceuticals Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global Radiopharmaceuticals Product Landscape
4.2.1 Analysis by Product Type
4.2.2 Analysis by End User
4.2.3 Analysis by Applications
5 Global Radiopharmaceuticals Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter’s Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Radiopharmaceuticals Market Segmentation
6.1 Global Radiopharmaceuticals Market, by Product Type
6.1.1 Market Overview
6.1.1.1 Diagnostic Nuclear Medicine
6.1.1.1.1 SPECT Radiopharmaceuticals
6.1.1.1.2 Technetium-99m
6.1.1.1.3 Thallium-201
6.1.1.1.4 Gallium-67
6.1.1.1.5 Iodine-123
6.1.1.1.6 Other
6.1.1.2 PET Radiopharmaceuticals
6.1.1.2.1 F-18
6.1.1.2.2 RU-82
6.1.1.2.3 Others
6.1.1.3 Therapeutic Nuclear Medicine
6.1.1.3.1 Alpha Emitters
6.1.1.3.2 Ra-223
6.1.1.4 Brachytherapy Isotopes
6.1.1.4.1 Intoiodine-125
6.1.1.4.2 Palladium-103
6.1.1.4.3 Cesium-131
6.1.1.4.4 Iridium-192
6.1.1.4.5 Other brachytherapy isotopes
6.1.1.5 Beta Emitters
6.1.1.5.1 Intoiodine-131
6.1.1.5.2 Yttrium-90
6.1.1.5.3 Samarium-153
6.1.1.5.4 Lutetium-177
6.1.1.5.5 Rhenium-186
6.1.1.5.6 Other beta emitters
6.2 Global Radiopharmaceuticals Market, by Applications
6.2.1 Market Overview
6.2.2 Diagnostic Applications
6.2.3 SPECT Applications
6.2.3.1 Cardiology
6.2.3.2 Bone Scans
6.2.3.3 Thyroid Applications
6.2.3.4 Pulmonary Scans
6.2.3.5 Other SPECT Applications
6.2.4 PET applications
6.2.4.1 Oncology
6.2.4.2 Cardiology
6.2.4.3 Neurology
6.2.4.4 Other PET applications
6.2.5 Therapeutic Applications
6.2.5.1 Thyroid Indications
6.2.5.2 Bone Metastasis
6.2.5.3 Lymphoma
6.2.5.4 Endocrine Tumors
6.2.5.5 Other Indications
6.3 Global Radiopharmaceuticals Market, by Volume Assessment
6.3.1 Market Overview
6.3.2 Diagnostic Procedures
6.3.3 Therapeutic Procedures
6.4 Global Radiopharmaceuticals Market, by Source
6.4.1 Market Overview
6.4.2 Nuclear Rectors
6.4.3 Cyclotrons
6.5 Global Radiopharmaceuticals Market, by End User
6.5.1 Market Overview
6.5.2 Hospitals
6.5.3 Ambulatory Surgical Centres
6.5.4 Diagnostic Centres
6.5.5 Cancer Research Institutes
6.5.6 Others
6.6 Global Radiopharmaceuticals Market by Region
6.6.1 Market Overview
6.6.2 North America
6.6.3 Europe
6.6.4 Asia Pacific
6.6.5 Latin America
6.6.6 Middle East and Africa
7 North America Radiopharmaceuticals Market
7.1 Market Share by Country
7.2 United States of America
7.3 Canada
8 Europe Radiopharmaceuticals Market
8.1 Market Share by Country
8.2 United Kingdom
8.3 Germany
8.4 France
8.5 Italy
8.6 Others
9 Asia Pacific Radiopharmaceuticals Market
9.1 Market Share by Country
9.2 China
9.3 Japan
9.4 India
9.5 ASEAN
9.6 Australia
9.7 Others
10 Latin America Radiopharmaceuticals Market
10.1 Market Share by Country
10.2 Brazil
10.3 Argentina
10.4 Mexico
10.5 Others
11 Middle East and Africa Radiopharmaceuticals Market
11.1 Market Share by Country
11.2 Saudi Arabia
11.3 United Arab Emirates
11.4 Nigeria
11.5 South Africa
11.6 Others
12 Patent Analysis
12.1 Analysis by Type of Patent
12.2 Analysis by Publication year
12.3 Analysis by Issuing Authority
12.4 Analysis by Patent Age
12.5 Analysis by CPC Analysis
12.6 Analysis by Patent Valuation
12.7 Analysis by Key Players
13 Grants Analysis
13.1 Analysis by year
13.2 Analysis by Amount Awarded
13.3 Analysis by Issuing Authority
13.4 Analysis by Grant Application
13.5 Analysis by Funding Institute
13.6 Analysis by NIH Departments
13.7 Analysis by Recipient Organization
14 Funding Analysis
14.1 Analysis by Funding Instances
14.2 Analysis by Type of Funding
14.3 Analysis by Funding Amount
14.4 Analysis by Leading Players
14.5 Analysis by Leading Investors
14.6 Analysis by Geography
15 Partnership and Collaborations Analysis
15.1 Analysis by Partnership Instances
15.2 Analysis by Type of Partnership
15.3 Analysis by Leading Players
15.4 Analysis by Geography
16 Regulatory Framework
16.1 Regulatory Overview
16.1.1 US FDA
16.1.2 EU EMA
16.1.3 INDIA CDSCO
16.1.4 JAPAN PMDA
16.1.5 Others
17 Supplier Landscape
17.1 Cardinal Health
17.1.1 Financial Analysis
17.1.2 Product Portfolio
17.1.3 Demographic Reach and Achievements
17.1.4 Mergers and Acquisitions
17.1.5 Certifications
17.2 GE Healthcare
17.2.1 Financial Analysis
17.2.2 Product Portfolio
17.2.3 Demographic Reach and Achievements
17.2.4 Mergers and Acquisitions
17.2.5 Certifications
17.3 Lantheus Medical Imaging
17.3.1 Financial Analysis
17.3.2 Product Portfolio
17.3.3 Demographic Reach and Achievements
17.3.4 Mergers and Acquisitions
17.3.5 Certifications
17.4 Bayer AG
17.4.1 Financial Analysis
17.4.2 Product Portfolio
17.4.3 Demographic Reach and Achievements
17.4.4 Mergers and Acquisitions
17.4.5 Certifications
17.5 Bracco Imaging
17.5.1 Financial Analysis
17.5.2 Product Portfolio
17.5.3 Demographic Reach and Achievements
17.5.4 Mergers and Acquisitions
17.5.5 Certifications
17.6 Nordion
17.6.1 Financial Analysis
17.6.2 Product Portfolio
17.6.3 Demographic Reach and Achievements
17.6.4 Mergers and Acquisitions
17.6.5 Certifications
17.7 NTP Radioisotopes
17.7.1 Financial Analysis
17.7.2 Product Portfolio
17.7.3 Demographic Reach and Achievements
17.7.4 Mergers and Acquisitions
17.7.5 Certifications
17.8 NorthStar Medical Radioisotopes
17.8.1 Financial Analysis
17.8.2 Product Portfolio
17.8.3 Demographic Reach and Achievements
17.8.4 Mergers and Acquisitions
17.8.5 Certifications
17.9 Eckert & Ziegler
17.9.1 Financial Analysis
17.9.2 Product Portfolio
17.9.3 Demographic Reach and Achievements
17.9.4 Mergers and Acquisitions
17.9.5 Certifications
17.10 Braun Melsungen AG
17.10.1 Financial Analysis
17.10.2 Product Portfolio
17.10.3 Demographic Reach and Achievements
17.10.4 Mergers and Acquisitions
17.10.5 Certifications
17.11 Smith Nephew
17.11.1 Financial Analysis
17.11.2 Product Portfolio
17.11.3 Demographic Reach and Achievements
17.11.4 Mergers and Acquisitions
17.11.5 Certifications
17.12 Zimmer Biomet
17.12.1 Financial Analysis
17.12.2 Product Portfolio
17.12.3 Demographic Reach and Achievements
17.12.4 Mergers and Acquisitions
17.12.5 Certifications
17.13 Hanger Inc.
17.13.1 Financial Analysis
17.13.2 Product Portfolio
17.13.3 Demographic Reach and Achievements
17.13.4 Mergers and Acquisitions
17.13.5 Certifications
17.14 Otto Bock Healthcare
17.14.1 Financial Analysis
17.14.2 Product Portfolio
17.14.3 Demographic Reach and Achievements
17.14.4 Mergers and Acquisitions
17.14.5 Certifications
18 Global Radiopharmaceuticals Market-Distribution Model (Additional Insight)
18.1 Overview
18.2 Potential Distributors
18.3 Key Parameters for Distribution Partner Assessment
19 Key Opinion Leaders (KOL) Insights (Additional Insight)
20 Company Competitiveness Analysis (Additional Insight)
20.1 Very Small Companies
20.2 Small Companies
20.3 Mid-Sized Companies
20.4 Large Companies
20.5 Very Large Companies
21 Pricing Models and Strategies (Additional Insight)
21.1 Overview
21.2 Cost Model
21.2.1 Manufacturing Cost Analysis
21.2.2 Procurement Cost Analysis
21.2.3 Clinical Trial Cost Factors
21.3 Pricing Strategies
21.3.1 Competitor Pricing Analysis
21.3.2 Key Assessment of Product Attributes
21.3.3 Pricing Benchmark

Companies Mentioned

  • Cardinal Health
  • Ge Healthcare
  • Lantheus Medical Imaging
  • Bayer AG
  • Bracco Imaging
  • Nordion
  • Ntp Radioisotopes
  • Northstar Medical Radioisotopes
  • Eckert & Ziegler
  • Braun Melsungen AG
  • Smith Nephew
  • Zimmer Biomet
  • Hanger Inc.
  • Otto Bock Healthcare

Methodology

Loading
LOADING...

Table Information